We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Transcription Factor Genes Kill Tumors

By Biotechdaily staff writers
Posted on 15 Feb 2005
Cancer researchers working with a rodent model for prostate cancer have used an adenovirus vector to implant the genes for two transcription factors, PEA-3 and AP-1, which selectively activated a tumor-suppressing gene and eradicated the cancer cells without harming normal tissues.

Investigators at Columbia University Medical Center (New York, NY, USA) created an adenovirus vector containing the genes for the transcription factors PEA-3 and AP-1. More...
These factors were known to trigger the conversion of inactive PROM-PEG cancer protein into active PEG-3 (progression-elevated gene-3), an apoptosis initiator. PROM-PEG is generally found in abundance in cancer cells but is not present in normal cells.

Results published in the January 25, 2005, issue of the Proceedings of the [U.S.] National Academy of Sciences revealed that tumors in mice receiving the vector died while normal tissues were not affected. The PEA-1/AP-1 combination was also found to act on melanoma, ovarian, breast, and glioma (brain) tumors.

"What is exciting is we may now be able to design a therapy that will seek out and destroy only cancer cells,” said senior author, Dr. Paul B. Fisher, professor of clinical pathology at Columbia University Medical Center. "We hope it will be particularly powerful in eradicating metastases that we cannot see and that cannot be eliminated by surgery or radiation. Gene therapy, especially for cancer, is really starting to make a comeback.”






Related Links:
Columbia University Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.